GlassScriptPhysician profile
Neil D Wallen
NPI 1326043373
$12,151.61
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $1,742 · 2021: $2,379 · 2022: $2,542 · 2023: $2,098 · 2024: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,650.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,968.05 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $1,513.45 | 2019-2024 | Haegarda, Hizentra |
| Genzyme Corporation | $1,441.85 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,372.07 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,135.43 | 2020-2024 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $1,002.12 | 2020-2024 | Dupixent |
| Kaleo, INC. | $935.54 | 2019-2024 | Auvi-Q |
| Amgen INC. | $801.45 | 2021-2024 | Tezspire |
| Shire North American Group INC | $399.42 | 2019 | |
| Biocryst US Sales Co., LLC | $237.69 | 2021-2024 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.22 | 2019-2022 | |
| Grifols USA, LLC | $183.39 | 2020-2024 | Xembify |
| Octapharma USA, INC. | $170.49 | 2021-2023 | Cutaquig |
| Pfizer INC. | $123.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $93.84 | 2020-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $85.58 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $84.99 | 2019-2022 | |
| Hospira, INC. | $77.19 | 2020-2021 | |
| Mylan Specialty L.P. | $55.33 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $44.60 | 2019-2020 | |
| Optinose US, INC. | $37.63 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $31.74 | 2019-2022 | |
| Circassia INC. | $22.63 | 2019 | |
| Abbvie INC. | $18.64 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $18.52 | 2020 | |
| Aimmune Therapeutics, INC. | $17.98 | 2022 | |
| Phadia US INC. | $14.80 | 2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Hikma Pharmaceuticals USA | $13.68 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Wallen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.